Blechman Foundation-funded study published in Science Translational Medicine
In June 2016, researchers at the University of Pittsburgh School of Medicine announced a major breakthrough from a study, funded in part by the Blechman Foundation, that explains why the Parkinson’s-related protein alpha-synuclein is toxic to neurons in the brain. The findings offer promise to identify new therapies that could slow or stop the progression of the degenerative illness, and were published in Science Translational Medicine (“a-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease”).
You can read the full text of the journal article below and the abstract here. For more information, please see the official press release and additional coverage from NPR and Altmetric.
Who We Are
The inspiration behind our cause is our mother, who was diagnosed with Parkinson’s in 2008. On behalf of our mom and others like her, we are committed to hastening progress in the fight against the disease. Let's get started. Continue reading
The Blechman Foundation funds neuroprotective research for Parkinson’s disease. Learn more